Business Description
GlaxoSmithKline Pakistan Ltd
ISIN : PK0001301016
Compare
Compare
Traded in other countries / regions
GLAXO.Pakistan IPO Date
1953-07-03Description
GlaxoSmithKline Pakistan Ltd is engaged in research, development, and manufacturing pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from Pharmaceuticals segment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 39.84 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 6.13 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.3 | |||||
| 3-Year EBITDA Growth Rate | -18.2 | |||||
| 3-Year EPS without NRI Growth Rate | -43 | |||||
| 3-Year Book Growth Rate | 7.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.4 | |||||
| 9-Day RSI | 50.63 | |||||
| 14-Day RSI | 57.08 | |||||
| 6-1 Month Momentum % | 156.43 | |||||
| 12-1 Month Momentum % | 332.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.68 | |||||
| Quick Ratio | 0.88 | |||||
| Cash Ratio | 0.33 | |||||
| Days Inventory | 110.23 | |||||
| Days Sales Outstanding | 6.22 | |||||
| Days Payable | 52.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.1 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 18.53 | |||||
| Operating Margin % | 12.71 | |||||
| Net Margin % | 8.02 | |||||
| FCF Margin % | 7.62 | |||||
| ROE % | 19.91 | |||||
| ROA % | 10.83 | |||||
| ROIC % | 14.93 | |||||
| ROC (Joel Greenblatt) % | 61.03 | |||||
| ROCE % | 30.25 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 28.24 | |||||
| PE Ratio without NRI | 27.54 | |||||
| Shiller PE Ratio | 35.91 | |||||
| Price-to-Owner-Earnings | 36.51 | |||||
| PS Ratio | 2.27 | |||||
| PB Ratio | 5.05 | |||||
| Price-to-Tangible-Book | 5.24 | |||||
| Price-to-Free-Cash-Flow | 29.71 | |||||
| Price-to-Operating-Cash-Flow | 19.6 | |||||
| EV-to-EBIT | 16.83 | |||||
| EV-to-EBITDA | 14.66 | |||||
| EV-to-Revenue | 2.21 | |||||
| EV-to-FCF | 29.02 | |||||
| Price-to-Projected-FCF | 3.28 | |||||
| Price-to-Median-PS-Value | 1.51 | |||||
| Price-to-Graham-Number | 2.53 | |||||
| Price-to-Net-Current-Asset-Value | 10.81 | |||||
| Earnings Yield (Greenblatt) % | 5.94 | |||||
| FCF Yield % | 3.27 | |||||
| Forward Rate of Return (Yacktman) % | -3.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GlaxoSmithKline Pakistan Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₨) | 56,233.27 | ||
| EPS (TTM) (₨) | 14.16 | ||
| Beta | 0 | ||
| Volatility % | 55.31 | ||
| 14-Day RSI | 57.08 | ||
| 14-Day ATR (₨) | 24.199472 | ||
| 20-Day SMA (₨) | 382.8475 | ||
| 12-1 Month Momentum % | 332.73 | ||
| 52-Week Range (₨) | 75.01 - 444 | ||
| Shares Outstanding (Mil) | 318.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GlaxoSmithKline Pakistan Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GlaxoSmithKline Pakistan Ltd Stock Events
| Event | Date | Price(₨) | ||
|---|---|---|---|---|
| No Event Data | ||||
GlaxoSmithKline Pakistan Ltd Frequently Asked Questions
What is GlaxoSmithKline Pakistan Ltd(KAR:GLAXO)'s stock price today?
The current price of KAR:GLAXO is ₨399.97. The 52 week high of KAR:GLAXO is ₨444.00 and 52 week low is ₨75.01.
When is next earnings date of GlaxoSmithKline Pakistan Ltd(KAR:GLAXO)?
The next earnings date of GlaxoSmithKline Pakistan Ltd(KAR:GLAXO) is .
Does GlaxoSmithKline Pakistan Ltd(KAR:GLAXO) pay dividends? If so, how much?
GlaxoSmithKline Pakistan Ltd(KAR:GLAXO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers